Shares of CHF Solutions Inc (NASDAQ:CHFS) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Brokerages have set a twelve-month consensus price objective of $44.12 for the company, according to Zacks. Zacks has also given CHF Solutions an industry rank of 93 out of 256 based on the ratings given to related companies.
Several equities analysts have commented on the company. Zacks Investment Research raised CHF Solutions from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a report on Tuesday, October 9th. ValuEngine raised CHF Solutions from a “hold” rating to a “buy” rating in a report on Wednesday, January 2nd.
CHF Solutions (NASDAQ:CHFS) last posted its quarterly earnings data on Tuesday, November 6th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.57) by ($0.04). CHF Solutions had a negative return on equity of 169.26% and a negative net margin of 459.89%. The business had revenue of $1.36 million for the quarter, compared to analyst estimates of $1.30 million. As a group, sell-side analysts predict that CHF Solutions will post -41.04 earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc acquired a new position in CHF Solutions in the 3rd quarter valued at approximately $39,000. Dimensional Fund Advisors LP acquired a new position in CHF Solutions in the 2nd quarter valued at approximately $161,000. Finally, Wexford Capital LP raised its holdings in CHF Solutions by 176.9% in the 3rd quarter. Wexford Capital LP now owns 391,809 shares of the company’s stock valued at $334,000 after acquiring an additional 250,300 shares in the last quarter. 14.08% of the stock is owned by hedge funds and other institutional investors.
CHF Solutions Company Profile
CHF Solutions, Inc, an early-stage medical device company, develops cardiac and coronary disease products primarily in the United States. The company focuses on commercializing the Aquadex FlexFlow system, which is indicated for temporary ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization.
See Also: What is the Dividend Aristocrat Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CHF Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CHF Solutions and related companies with MarketBeat.com's FREE daily email newsletter.